GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
GSK (NYSE:GSK) had its "underweight" rating reaffirmed by analysts at Barclays PLC.
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
GSK (NYSE:GSK) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..